Blood-brain barrier leakage after status epilepticus in rapamycin-treated rats I: Magnetic resonance imaging

Epilepsia

Volumn 57, Issue 1, 2016, Pages 59-69

  Van Vliet, Erwin A ^a   Otte, Willem M ^b,c   Wadman, Wytse J ^d,e   Aronica, Eleonora ^a   Kooij, Gijs ^f   De Vries, Helga E ^f   Dijkhuizen, Rick M ^b   Gorter, Jan A ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blood brain barrier; Contrast enhanced magnetic resonance imaging; Epileptogenesis; Rapamycin; Status epilepticus; Temporal lobe epilepsy

Indexed keywords

AMINO ACID RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; CONTRAST AGENT BR1; KAINIC ACID; PHOSPHOLIPID; RAPAMYCIN; SULFUR HEXAFLUORIDE;

ANIMAL; BLOOD; BLOOD BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; FOLLOW UP; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; STATUS EPILEPTICUS; TIME FACTOR; VIDEORECORDING;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID AGONISTS; FOLLOW-UP STUDIES; KAINIC ACID; MAGNETIC RESONANCE IMAGING; MALE; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; STATUS EPILEPTICUS; SULFUR HEXAFLUORIDE; TIME FACTORS; VIDEO RECORDING;

EID: 84954078543     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13246     Document Type: Article

References (27)

1. Mihaly A, Bozoky B,. Immunohistochemical localization of extravasated serum albumin in the hippocampus of human subjects with partial and generalized epilepsies and epileptiform convulsions. Acta Neuropathol (Berl) 1984; 65: 25-34.
2. Van Vliet EA, da Costa Araújo S, Redeker S, et al., Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007; 130: 521-534.
3. Liu JY, Thom M, Catarino CB, et al., Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 2012; 135: 3115-3133.
4. Rigau V, Morin M, Rousset MC, et al., Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 2007; 130: 1942-1956.
5. Tomkins O, Kaufer D, Korn A, et al., Frequent blood-brain barrier disruption in the human cerebral cortex. Cell Mol Neurobiol 2001; 21: 675-691.
6. Nitsch C, Klatzo I,. Regional patterns of blood-brain barrier breakdown during epileptiform seizures induced by various convulsive agents. J Neurol Sci 1983; 59: 305-322.
7. Leroy C, Roch C, Koning E, et al., In the lithium-pilocarpine model of epilepsy, brain lesions are not linked to changes in blood-brain barrier permeability: an autoradiographic study in adult and developing rats. Exp Neurol 2003; 182: 361-372.
8. Ravizza T, Gagliardi B, Noe F, et al., Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 2008; 29: 142-160.
9. Ivens S, Kaufer D, Flores LP, et al., TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 2007; 130: 535-547.
10. Seiffert E, Dreier JP, Ivens S, et al., Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J Neurosci 2004; 24: 7829-7836.
11. Vezzani A, French J, Bartfai T, et al., The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7: 31-40.
12. Marchi N, Granata T, Ghosh C, et al., Blood-brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approaches. Epilepsia 2012; 53: 1877-1886.
13. Korn A, Golan H, Melamed I, et al., Focal cortical dysfunction and blood-brain barrier disruption in patients with Postconcussion syndrome. J Clin Neurophysiol 2005; 22: 1-9.
14. Cacheaux LP, Ivens S, David Y, et al., Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. J Neurosci 2009; 29: 8927-8935.
15. Van Vliet EA, Forte G, Holtman L, et al., Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation. Epilepsia 2012; 53: 1254-1263.
16. Van Vliet EA, Otte WM, Gorter JA, et al., Longitudinal assessment of blood-brain barrier leakage during epileptogenesis in rats. A quantitative MRI study. Neurobiol Dis 2014; 63: 74-84.
17. Racine RJ,. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972; 32: 281-294.
18. Qiao X, Werkman TR, Gorter JA, et al., Expression of sodium channel alpha subunits 1.1, 1.2 and 1.6 in rat hippocampus after kainic acid-induced epilepsy. Epilepsy Res 2013; 106: 17-28.
19. Paxinos G, Watson C,. The rat brain in stereotaxic coordinates. San Diego, CA: Academic Press; 1998.
20. Narayanan SP, Flores AI, Wang F, et al., Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci 2009; 29: 6860-6870.
21. Bootun R,. Effects of immunosuppressive therapy on wound healing. Int Wound J 2013; 10: 98-104.
22. Nashan B, Citterio F,. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation 2012; 94: 547-561.
23. van Vliet EA, Aronica E, Gorter JA,. Blood-brain barrier dysfunction, seizures and epilepsy. Semin Cell Dev Biol 2015; 38: 26-34.
24. Huang X, Zhang H, Yang J, et al., Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis 2010; 40: 193-199.
25. Sliwa A, Plucinska G, Bednarczyk J, et al., Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Neurosci Lett 2012; 509: 105-109.
26. Fingar DC, Salama S, Tsou C, et al., Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002; 16: 1472-1487.
27. Houde VP, Brule S, Festuccia WT, et al., Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010; 59: 1338-1348.